Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Disease Modification in Alzheimer's Disease: Current Thinking.

Liu-Seifert H, Schumi J, Miao X, Tian Y, Rabbia M, Andersen SW, Wilson S, Li W, Entsuah R.

Ther Innov Regul Sci. 2020 Mar;54(2):396-403. doi: 10.1007/s43441-019-00068-4. Epub 2020 Jan 6. Review.

PMID:
32072596
2.

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.

Monk SA, Kugler AR, Andersen SW, Ayan-Oshodi MA, James DE, Mullen J, Zimmer JA, Willis BA.

J Clin Pharmacol. 2019 Dec 18. doi: 10.1002/jcph.1558. [Epub ahead of print]

PMID:
31853995
3.

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.

Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR.

JAMA Neurol. 2019 Nov 25. doi: 10.1001/jamaneurol.2019.3988. [Epub ahead of print]

4.

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.

Willis BA, Andersen SW, Ayan-Oshodi M, James DE, Liffick E, Hillgren K, Guo Y, Monk SA.

J Clin Pharmacol. 2020 Jan;60(1):107-116. doi: 10.1002/jcph.1500. Epub 2019 Aug 5.

PMID:
31378968
5.

Does religious involvement affect mortality in low-income Americans? A prospective cohort study.

Wen W, Schlundt D, Andersen SW, Blot WJ, Zheng W.

BMJ Open. 2019 Jul 9;9(7):e028200. doi: 10.1136/bmjopen-2018-028200.

6.

Disease Modification in Alzheimer's Disease: Current Thinking.

Liu-Seifert H, Schumi J, Miao X, Tian Y, Rabbia M, Andersen SW, Wilson S, Li W, Entsuah R.

Ther Innov Regul Sci. 2019 Apr 14:2168479019841894. doi: 10.1177/2168479019841894. [Epub ahead of print]

PMID:
30983382
7.

Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study.

Sanderson M, Lipworth L, Shrubsole MJ, Andersen SW, Shu XO, Zheng W, Hargreaves MK, Blot WJ.

Cancer Causes Control. 2019 May;30(5):425-433. doi: 10.1007/s10552-019-01164-4. Epub 2019 Apr 2.

PMID:
30941541
8.

Survival benefits associated with surgery for advanced non-small cell lung cancer.

David EA, Andersen SW, Beckett LA, Melnikow J, Clark JM, Brown LM, Cooke DT, Kelly K, Canter RJ.

J Thorac Cardiovasc Surg. 2019 Apr;157(4):1620-1628. doi: 10.1016/j.jtcvs.2018.10.140. Epub 2018 Nov 14.

9.

Derivation of cutoffs for the Elecsys® amyloid β (1-42) assay in Alzheimer's disease.

Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, Eichenlaub U, Wahl S, Quan M, Pontecorvo MJ, Lachno DR, Talbot JA, Andersen SW, Siemers ER, Dean RA.

Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.

10.

The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial.

Wessels AM, Andersen SW, Dowsett SA, Siemers ER.

J Prev Alzheimers Dis. 2018;5(2):134-136. doi: 10.14283/jpad.2018.10.

PMID:
29616706
11.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.

PMID:
29405226
12.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients.

David EA, Andersen SW, Beckett LA, Melnikow J, Kelly K, Cooke DT, Brown LM, Canter RJ.

Ann Thorac Surg. 2017 Nov;104(5):1665-1672. doi: 10.1016/j.athoracsur.2017.05.071. Epub 2017 Sep 28.

13.

Total and Free Circulating Vitamin D and Vitamin D-Binding Protein in Relation to Colorectal Cancer Risk in a Prospective Study of African Americans.

Andersen SW, Shu XO, Cai Q, Khankari NK, Steinwandel MD, Jurutka PW, Blot WJ, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1242-1247. doi: 10.1158/1055-9965.EPI-17-0133. Epub 2017 May 8.

14.

Impact of a student-led community education program to promote Pap test screening among Asian-American women.

Miller KM, Ha DF, Chan RK, Andersen SW, Howell LP.

J Am Soc Cytopathol. 2017 Jul - Aug;6(4):145-154. doi: 10.1016/j.jasc.2017.03.004. Epub 2017 Apr 5.

PMID:
31043267
15.

A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).

Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS.

J Prev Alzheimers Dis. 2015 Dec 1;2(4):227-241.

16.

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.

Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P.

Alzheimers Dement (N Y). 2015 Jul 26;1(2):111-121. doi: 10.1016/j.trci.2015.06.006. eCollection 2015 Sep.

17.

A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease.

Liu-Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E.

PLoS One. 2015 Mar 17;10(3):e0119632. doi: 10.1371/journal.pone.0119632. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0131338.

18.

Possible Endpoints in a Prodromal Alzheimer's Disease Trial.

Wessels AM, Andersen SW, Castelluccio P, Zhang Z, Yu P.

J Prev Alzheimers Dis. 2015;2(2):88-90. doi: 10.14283/jpad.2015.52. No abstract available.

PMID:
29231229
19.

Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.

Andersen SW, Trentham-Dietz A, Figueroa JD, Titus LJ, Cai Q, Long J, Hampton JM, Egan KM, Newcomb PA.

Menopause. 2013 Mar;20(3):354-8. doi: 10.1097/GME.0b013e318268ca46.

20.

On the practical application of mixed effects models for repeated measures to clinical trial data.

Andersen SW, Millen BA.

Pharm Stat. 2013 Jan-Feb;12(1):7-16. doi: 10.1002/pst.1548. Epub 2012 Dec 13.

PMID:
23239585
21.
22.

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.

Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD.

J Clin Psychopharmacol. 2004 Aug;24(4):365-73.

PMID:
15232326
23.

Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dubé S.

J Clin Psychiatry. 2003 Nov;64(11):1349-56. Erratum in: J Clin Psychiatry. 2004 Feb;65(2):279.

PMID:
14658950
24.

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.

Pharmacoeconomics. 2000 Dec;18(6):567-79.

PMID:
11227395
25.
26.

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?

Tollefson GD, Andersen SW.

J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. Review.

27.

Echoplanar BOLD fMRI of brain activation induced by concurrent transcranial magnetic stimulation.

Bohning DE, Shastri A, Nahas Z, Lorberbaum JP, Andersen SW, Dannels WR, Haxthausen EU, Vincent DJ, George MS.

Invest Radiol. 1998 Jun;33(6):336-40.

PMID:
9647445
28.

[Psychiatry--better services for schizophrenic youth].

Andersen SW.

Sygeplejersken. 1998 Jan 2;98(1):32-5. Danish. No abstract available.

PMID:
9485904
29.

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD.

J Clin Psychopharmacol. 1997 Oct;17(5):407-18.

PMID:
9315992
30.

Acupuncture treatment of patients with radiation-induced xerostomia.

Andersen SW, Machin D.

Oral Oncol. 1997 Mar;33(2):146-7. No abstract available.

PMID:
9231175

Supplemental Content

Loading ...
Support Center